Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 25 Sep 2019

Healthcare personnel (HCP) who use medical masks when in contact with patients with respiratory illness are no more likely to acquire influenza or other viral respiratory illnesses than HCPs who use N95 respirators, according to the ResPECT* study.

Advancing the treatment paradigm of idiopathic pulmonary fibrosis (IPF)

22 Jan 2018
Literature suggests that IPF is either the first or second most common interstitial lung disease (ILD) in pulmonology practice, with prevalence ranging from 17–86%. At the recent 3rd Respiratory Forum organized by Boehringer Ingelheim, Dr Felix Chua shared his insights into the importance of advancing the treatment paradigm of IPF, and the role of nintedanib (OFEV®) in its management.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 25 Sep 2019

Healthcare personnel (HCP) who use medical masks when in contact with patients with respiratory illness are no more likely to acquire influenza or other viral respiratory illnesses than HCPs who use N95 respirators, according to the ResPECT* study.